<DOC>
	<DOCNO>NCT01637012</DOCNO>
	<brief_summary>To evaluate safety effectiveness ALEX stent real-world set percutaneous coronary intervention patient coronary heart disease .</brief_summary>
	<brief_title>Prospective , Single-arm , Multicenter Study Evaluation Safety Effectiveness ALEX Stent Real-world Setting Percutaneous Coronary Interventions Patients With Coronary Heart Disease</brief_title>
	<detailed_description>Prospective , multicenter , non-randomized study design enroll 60 subject evaluate safety effectiveness cobalt-chromium sirolimus elute coronary stent ALEX real-world set percutaneous coronary intervention patient coronary heart disease .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Clinical &gt; 18 year age Patient must provide write informed consent prior procedure use form approve local Ethics Committee clinical diagnosis Stable Angina , Unstable Angina Myocardial Infarction without ST elevation ( NSTEMI ) Myocardial Infarction ST elevation provide expiry 72 hour onset symptom stable clinical hemodynamical condition Patient patent postinfarcion artery ( TIMI 3 ) indication PCI next stage revascularization vessel earlier effective supply others lesion others vessel case multivessels disease female childbearing potential must negative pregnancy test within 7 day prior enrolment utilize reliable birth control 12 month enrolment Angiographic Inclusion Criteria target lesion stentosis must &gt; 70 % ( visual estimate ) Patient eligible PCI treatment ALEX stent system ( vessel diameter range 2.5 4.0 mm length lesion allow cover single stent maximum length 30 mm visual evaluation ) Clinical Exclusion Criteria anticipate inablility patient comply 12 month antiplatelet treatment ( e. g. elective noncardiac surgery follow stenting , drug intolerance etc . ) acute chronic renal failure ( serum creatinine &gt; 2 mg % , GFR &lt; 60 ml/min/1.73m2 ) leave ventricular ejection fraction ( LVEF ) &lt; 40 % cardiogenic shock short life expectancy ( &lt; 1 year ) significant medical condition investigator 's opinion may interference Patient 's optimal participation study current participation another drug device clinical trail reach primary endpoint clinically interferences trail 's enpoints Angiographic Exclusion Criteria chronic total occlusion calcify lesion successfully dilate location lesion wind vessel possibility OCT image target stenosis locate venous arterial bridge unprotected leave main coronary disease &gt; 50 % stenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>ALEX</keyword>
	<keyword>coronary stent</keyword>
	<keyword>cobalt-chromium</keyword>
	<keyword>sirolimus</keyword>
	<keyword>OCT</keyword>
</DOC>